Market Place
Sourcing Support
Novartis` Generic Tafinlar (Dabrafenib) Receives Approval in the U.S.
16 Mar 2023 //
FDA
JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor
03 Jan 2023 //
BUSINESSWIRE
Spirita Oncology, LLC Initiates a Ph1 Trial of the Anti-Cancer Agent E6201
30 Nov 2022 //
BUSINESSWIRE
Novartis drug combo shows promise in childhood brain cancer
07 Jun 2022 //
REUTERS
Novartis Presents Data From PhIII Trial Of Spartalizumab With Tafinlar &Mekinist
20 Sep 2020 //
PRESS RELEASE
Novartis` Tafinlar/Mekinist combo improves survival in new Phase 3 data
17 Sep 2020 //
PHARMA FILE
Novartis Tafinlar+ Mekinis demonstrates survival in stage III melanoma
16 Sep 2020 //
GLOBENEWSWIRE
Novartis’ spartalizumab misses primary goal in melanoma study
24 Aug 2020 //
CLINICALTRIALS
Novartis` melanoma combo fails in PhIII
23 Aug 2020 //
PHARMATIMES
Targeted therapy combination effective for patients with cholangiocarcinoma
18 Aug 2020 //
NEWSBREAK
Array BioPharma’s Triple-Drug Combo Could be Gamechanger for Colorectal Cancer
08 Jul 2019 //
BIOSPACE
Long-term Survival Benefit Shown for Tafinlar + Mekinist in Metastatic Melanoma
04 Jun 2019 //
PR NEWSWIRE
Novartis wins key adjuvant Taf/Mek approval in Europe
29 Aug 2018 //
PM LIVE
FDA approves simultaneous administration of Tafinlar, Mekinist for ATC
09 May 2018 //
IN PHARMATECHNOLOGIST
FDA approves two drugs combined to treat aggressive thyroid cancer
04 May 2018 //
XINHUANET
FDA approval for Novartis` melanoma combo
01 May 2018 //
PHARMA TIMES
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant BRAF V600
30 Apr 2018 //
PR NEWSWIRE
Novartis` combination therapy Tafinlar Mekinist granted FDA Review adjuvant
22 Dec 2017 //
PR NEWSWIRE
Novartis combo therapy for melanoma gets FDA priority review
22 Dec 2017 //
REUTERS
Novartis gets FDA breakthrough status for Tafinlar, Mekinist combination
24 Oct 2017 //
REUTERS
Novartis edges Roche in melanoma with adjuvant `breakthrough`
23 Oct 2017 //
FIERCE PHARMA
Novartis receives US FDA nod for Tafinlar in combo with Mekinist for BRAF V600E
23 Jun 2017 //
PHARMABIZ
Novartis: FDA Approves Tafinlar Plus Mekinist For BRAF V600E-mutant NSCLC
23 Jun 2017 //
NASDAQ
Novartis announces clinical collaboration with BMS
05 Jun 2017 //
GLOBENEWSWIRE
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
01 Jun 2017 //
FIERCE BIOTECH
Array adds Ono as Japanese partner for MEK/BRAF combo
31 May 2017 //
FIERCE BIOTECH
Novartis` targeted meds Tafinlar, Mekinist pick up EU combo approval
05 Apr 2017 //
FIERCE PHARMA
Novartis gets lung cancer OK for Tafinlar/Mekinist combo
03 Apr 2017 //
PMLIVE
Novartis: Tafinlar + Mekinist Gets EU Approval For BRAF V600-positive NSCLC
03 Apr 2017 //
NASDAQ
EMA committee recommends approval of Novartis` Tafinlar + Mekinist
27 Feb 2017 //
PHARMABIZ
J&J gets CHMP backing for broader Darzalex use
27 Feb 2017 //
PMLIVE
Novartis wins CHMP nod for drug combo against some lung cancers
25 Feb 2017 //
REUTERS
How Precision Medicine Could Be A Lifesaver For Kids With Brain Cancer
19 Jan 2017 //
FORBES
Novartis` show superior survival benefit in advanced melanoma in phase III
11 Oct 2016 //
PHARMABIZ
AZ approval for Tagrisso in Japan a big change to NSCLC treatment option in Asia
30 Mar 2016 //
FIERCE PHARMA ASIA
Anvisa approves drugs for cancer and polio vaccine to 1.2 and 3
11 Jan 2016 //
ANVISA
Novartis receives FDA regular approval for Tafinlar® + Mekinist®
20 Nov 2015 //
MULTIVU
Roche wins first approval for skin cancer drug Cotellic
31 Aug 2015 //
PM LIVE
Novartis melanoma, anaemia drugs win CHMP favour
27 Jul 2015 //
PHARMA TIMES
Novartis unleashes M&A scouts as GSK deal starts to deliver on margins
23 Apr 2015 //
FIERCE PHARMA
Novartis has fresh data to support newly acquired CLL drug Arzerra
15 Apr 2015 //
FIERCE PHARMA
Gsk and Novartis Asset Swap: A Tale of Two Companies
14 Mar 2015 //
PMLIVE
GSK Deal`s Done. Now, Novartis Has To Deliver On Cancer-Growth Pledge
03 Mar 2015 //
FIERCE PHARMA
